# Scientific Project 3: Covid Immune response to SARS-CoV-2 natural infection followed by vaccination

> **NIH NIH U19** · SEATTLE CHILDREN'S HOSPITAL · 2022 · $127,742

## Abstract

HIPC3 Scientific Project 3: Immune response to SARS-CoV-2 natural infection followed by vaccination
Abstract
This project will characterize the innate and adaptive immune response to SARS-CoV-2 natural infection in the
setting of mild disease and follow-on vaccination. We will define signatures correlating with reduced viral
shedding, progression to PASC or long COVID, and magnitude of adaptive immune responses in
convalescence and after vaccination. Our approach uses cutting-edge multi-omic single-cell technologies to
dissect the innate and adaptive immune response and identify correlates of protection, vaccine response, and
PASC. We will 1. Define the innate immune response during acute infection and test the hypothesis that
interindividual variation in viral shedding duration is partly regulated by differences in innate response. These
analyses will also include diverse participants to identify potential contributions by race/ethnicity. 2. Track the
evolution and kinetics of T cell responses to natural infection and follow-on vaccination. We hypothesize that
specific targeted epitopes and phenotypes will be more protective in short viral shedding, and that vaccines
induce unique, protective T cells that are not found in the convalescent repertoire. These studies will also
identify key helper T cell phenotypes for mounting robust humoral and cellular responses to natural infection
and vaccine. These signatures will also be correlated with innate immune signatures to identify innate-adaptive
coordination events 3. Characterize the immune response throughout infection and convalescence in PASC.
Innate and adaptive immunity will be analyzed from acute infection through convalescence to understand how
inflammation and antiviral response trajectories may differ in PASC compared to successful recovery. These
will enable hypotheses on the causal mechanisms of PASC and therapeutic targets from ongoing pathogenic
mechanisms. These results will enable improved clinical outcomes, treatment of existing PASC patients, and
can guide vaccine developments and boosters. Overall, our longitudinal analysis will associate immune
responses throughout disease to concrete functional outcomes including duration of viral shedding, PASC, and
vaccine response.

## Key facts

- **NIH application ID:** 10419586
- **Project number:** 2U19AI128914-07
- **Recipient organization:** SEATTLE CHILDREN'S HOSPITAL
- **Principal Investigator:** aarthi talla
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $127,742
- **Award type:** 2
- **Project period:** 2017-07-19 → 2027-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10419586

## Citation

> US National Institutes of Health, RePORTER application 10419586, Scientific Project 3: Covid Immune response to SARS-CoV-2 natural infection followed by vaccination (2U19AI128914-07). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10419586. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*